This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
HCPLive
OCTOBER 27, 2024
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
133 
Circulation
JANUARY 27, 2025
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
HCPLive
OCTOBER 26, 2024
Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease care.
HCPLive
JUNE 5, 2024
In our nephrology month in review for May 2024, we spotlight the biggest news from the NKF and ERA meetings, including the latest updates in IgA nephropathy, C3 glomerulopathy, chronic kidney disease, and more!
HCPLive
MAY 2, 2024
This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.
HCPLive
MARCH 13, 2024
The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease is an update to the KDIGO 2012 CKD Guideline.
The British Journal of Cardiology
MARCH 4, 2025
57 These are some of the reasons that the combination of cardiac and renal disease strike fear into even the most seasoned clinicians. The complexity of this population drives their exclusion from clinical trials, resulting in a scarcity of evidence supporting any optimal treatment strategy.
Circulation
JANUARY 24, 2024
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
HCPLive
JANUARY 19, 2024
On January 19, 2024, the FDA announced the addition of a Boxed Warning to the labeling of denosumab (Prolia), citing evidence of an increased risk of severe hypocalcemia in patients with chronic kidney disease.
Circulation
SEPTEMBER 22, 2024
Circulation, Volume 150, Issue 13 , Page 975-977, September 24, 2024.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4145373-A4145373, November 12, 2024. Background:There have been several studies postulating the association between Mitral valve stenosis (MS) and Chronic Kidney Disease (CKD).
The American Journal of Cardiology
JUNE 12, 2024
Publication date: Available online 12 June 2024 Source: The American Journal of Cardiology Author(s): Nader Mankerious, Ralph Toelg, Birgit Vogel, Samantha Sartori, Dominick J. Angiolillo, Pascal Vranckx, Yihan Feng, Jose M. De la Torre Hernandez, Mitchell W. Krucoff, Deepak L. Bhatt, Alessandro Spirito, Davide Cao, Bassem M.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4142036-A4142036, November 12, 2024. Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidney disease (CKD). However, the association of former and current smoking status (vs.
HCPLive
AUGUST 23, 2024
Key opinion leaders analyze EULAR 2024 updates on gout, chronic inflammation's systemic impact, and gout-chronic kidney disease (CKD) connections, while examining urate-lowering therapies for gout management, particularly in patients with CKD.
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWP159-AWP159, February 1, 2024. Introduction:Chronic kidney disease (CKD) is a well-established risk factor for spontaneous intracerebral hemorrhage (ICH). However, the biological pathway underlying this association remains unclear.
The American Journal of Cardiology
OCTOBER 23, 2024
Publication date: Available online 22 October 2024 Source: The American Journal of Cardiology Author(s): Nathan W. Kong, Joseph M. Kim, Anna K. Krawisz, Patrick Heindel, Archana Tale, Yang Song, Jeffrey L. Weinstein, Mohamad A. Hussain, Eric A.
GEMMS
MAY 22, 2024
Gene-Based Analysis Predictive analytics is vital in reducing morbidity and mortality, with healthcare startups focusing on early risk prediction and disease detection. Much of heart disease is linked to conditions like diabetes, obesity, or chronic kidney disease, and specific mutations in nucleic acids help identify them.
The American Journal of Cardiology
OCTOBER 5, 2024
Publication date: Available online 5 October 2024 Source: The American Journal of Cardiology Author(s): Meghana Iyer, Khaled Ziada, Leslie Cho, Jacqueline Tamis-Holland, Umesh Khot, Amar Krishnaswamy, Rishi Puri, Samir Kapadia, Grant W Reed
The American Journal of Cardiology
DECEMBER 13, 2023
Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): David Song, Yasar Sattar, Mohammed Faisaluddin, Usama Talib, Neel Patel, Izza Shahid, Amro Taha, Fnu Raheela, Prasana Sengodon, Maria Riasat, Vaibhav Shah, Karthik Gonuguntla, Mahboob Alam, Islam Elgendy, Ramesh Daggubati, M. Chadi Alraies
40 
Clinical Trial Results
NOVEMBER 18, 2024
Tuttle_Bakris AHA 2024 FLOW kidney outcomes by BL CV_8Nov2024 Download Disclosures: TBD
40 
HCPLive
AUGUST 14, 2024
Key opinion leaders analyze EULAR 2024 updates on gout, chronic inflammation's systemic impact, and gout-chronic kidney disease (CKD) connections, while examining urate-lowering therapies for gout management, particularly in patients with CKD.
DAIC
JANUARY 18, 2024
Photo: Business Wire milla1cf Thu, 01/18/2024 - 14:05 January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for patients with below-knee peripheral arterial disease (PAD) were performed successfully using its Finesse Injectable balloon catheter platform. “All
105 
The American Journal of Cardiology
DECEMBER 13, 2023
Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): Kaiyong Xiao, Huili Cao, Liang Liu, Bin Yang, Huwei Dai, Sirong Wang, Ruining Li, Zeyu Wen, Zhaoshan Lu, Lian Xiao, Zhou Kang, Hui Feng
The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Cardiometabolic Health Congress
JUNE 24, 2024
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
52 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141474-A4141474, November 12, 2024. Logistic regression was used to determine the association between 5-HTP levels and calcification severity, adjusting for age, gender, smoking status, chronic kidney disease, hyperlipidemia, and diabetes. 95% CI = 2.6 to 40686.5).
Cardiometabolic Health Congress
AUGUST 14, 2024
14, 2024 (GLOBE NEWSWIRE) — For nearly two decades, Dr. George L. Taking place October 17-19, 2024, at The Boston Park Plaza, MA, this is a must-attend event for healthcare professionals across all specialties and sectors. Bakris’ distinguished career as a leading educator and mentor. Boca Raton, FL, Aug.
72 Circulation: Heart Failure
NOVEMBER 25, 2024
Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. More recently, the nonsteroidal MRA finerenone improved the HF outcomes of patients with HF with preserved ejection fraction, expanding the benefits previously seen among patients with diabetes and albuminuric chronic kidney disease.
Journal of Cardiovascular Pharmacology
MARCH 13, 2024
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. CVD and kidney disease are closely related, with kidney injury increasing CVD mortality. CVD and kidney disease are closely related, with kidney injury increasing CVD mortality. All rights reserved.
The British Journal of Cardiology
OCTOBER 8, 2024
In clinical trials and ‘real-world’ observational studies in people with and without diabetes, SGLT2 inhibitors have offered protection against heart failure and chronic kidney disease, while GLP-1 receptor agonists have been associated with reductions in atherosclerotic cardiovascular events and albuminuria.
40 
Journal of Cardiovascular Pharmacology
OCTOBER 9, 2024
Cox regression analysis revealed chronic kidney disease (CKD) (hazard ratio (HR) 2.05, 95% confidence interval (CI) [1.04,4.05] (p= 0.038)] and warfarin use [(HR 4.94, 95% CI [1.11,22.09] (p= 0.037)] to be independent predictors of mortality at 12 months. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4113864-A4113864, November 12, 2024. Patients with hyperkalemia had a higher frequency of diabetes mellitus, hypertension, chronic liver disease, acute kidney injury, chronic kidney disease, end-stage renal disease, and acute encephalopathy (p<0.001).
40 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4148106-A4148106, November 12, 2024. Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The hemophilia cohort was slightly older (63.2[16.8]
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4147019-A4147019, November 12, 2024. However, multi-parametric techniques and biomarkers which are available for investigating cardiovascular diseases and kidney diseases may offer opportunities for the evaluation of CRS.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4145609-A4145609, November 12, 2024. Introduction:Cannabis has been increasingly used as a recreational drug. Its cardiovascular effects depend on several factors, including the exact composition, route of administration, dose, and duration of use. He was euvolemic on physical exam.
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141279-A4141279, November 12, 2024. Background:Slow flow phenomenon is impaired coronary flow during percutaneous coronary intervention (PCI) in absence of mechanical obstruction, and it is associated with deteriorated outcome. The relationship between salvage index and FSF was shown in figure1.
40 Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWP252-AWP252, February 1, 2024. vs. 6.9%, SD 0.1), chronic kidney disease (1.9% Introduction:Migraine is a risk factor for cerebral ischemic stroke. However, it is not known if migraine is a risk factor for retinal stroke (central retinal artery occlusion, CRAO).Methods:We
40 Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWMP80-AWMP80, February 1, 2024. vs 63.38, p<0.001) and had fewer comorbidities such as cancer and chronic kidney disease, atrial fibrillation, hypertension, hyperlipidemia. We observed an increasing trend of ICH among pregnant individuals. vs 16.2%, p<0.001).
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146863-A4146863, November 12, 2024. Introduction:The treatment of heart failure (HF) with hydralazine-isosorbide dinitrate (H-ISDN) in African Americans (AA) with New York Heart Association (NYHA) III-IV who remain symptomatic despite optimal medical therapy is a class Ia indication.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4143897-A4143897, November 12, 2024. Background:Dietary magnesium (Mg+2) deficiency has been linked to hypertension, chronic kidney disease, and cardiovascular disease. High sodium intake and reduced dietary Mg+2consumption are associated with elevated blood pressure.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4143844-A4143844, November 12, 2024.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4137914-A4137914, November 12, 2024. This included an HbA1c>7.0%, age>50 with established CVD, heart failure, or chronic kidney disease or an age>60 with at least one CVD risk factor. year follow-up time).Results:Among Results:Among 5002 (projected to 34.0
40 Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWP278-AWP278, February 1, 2024. Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE.
40 
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page A52-A52, February 1, 2024. million by 2030 according to the Global Burden of Disease Study. Autoimmune diseases are increasingly associated with chronic conditions and may modify risks by altering underlying pathophysiology. to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content